Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events

IntroductionDespite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpoint blockade (ICB, PD-1 (+/-) CTLA-4 antibodies) i...

Повний опис

Бібліографічні деталі

Автори:	Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2024-06-01
Серія:	Frontiers in Immunology
Предмети:	uveal melanoma immune checkpoint blockade PD-1 CTLA-4 immune-related adverse events
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1395225/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!